

- Cimetidine
 action of, 332e-8
 adverse effects of
 arthralgias, 2218t
 cholestatic hepatitis, 284
 erectile dysfunction, 1920
 myopathy, 462e-20
 SA node dysfunction, 1467t
 thrombocytopenia, 727t
 for carcinoid syndrome, 566
 drug interactions of, 42t
 altretamine, 103e-9t
 chloroquine, 246e-1t
 macrolides, 939t
 mebendazole, 246e-3t
 metronidazole, 246e-5t
 PDE-5 inhibitors, 328
 phenytoin, 1920
 praziquantel, 246e-12
 quinidine, 246e-6t
 quinine, 246e-13
 theophylline, 1920
 warfarin, 1920
 for gastrinoma, 2337
 for GERD, 263
 for peptic ulcer disease, 1920, 1920t
 as premedication for antivenom, 2737
 as premedication for taxanes, 103e-15
- Cinacalcet, 1816
- CINCA (chronic infantile neurologic cutaneous and articular syndrome), 372e-8t
- Cingulate cortex, 180
- Cinnarizine, 2611
- Ciprofloxacin
 action of, 931t, 932-933, 943
 adverse effects of, 203, 246e-6t, 943, 2023, 2025t
 for *Aeromonas* infections, 183e-2, 183e-2t
 for anthrax, 261e-3, 261e-5t
 for *Bartonella* infections, 1081t
 for bite-wound infections, 167e-3, 167e-3t, 832t
 for bronchiectasis prophylaxis, 1696
 for burn-wound infections, 166e-3
 for *Campylobacter* infections, 1061
 for chancroid, 880t, 1013
 for cholera, 1064
 for clostridial infections, 991t
 for community-acquired pneumonia, 767t, 808t
 drug interactions of, 246e-6t
 for enteric fever, 1052t
 for febrile neutropenia, 103e-23
 for gonococcal arthritis, 835
 gut microbiota and, 86e-7
 for health care-associated pneumonia, 812t
 indications for, 246e-6t, 941t, 943
 for infections in cancer patient, 491
 for infectious diarrhea, 268, 857t
 for intraabdominal infections, 767t
 for *Legionella* infections, 1020t
 for necrotizing fasciitis, 832t
 for nongonococcal bacterial arthritis, 835
 for nontyphoidal *Salmonella* infections, 1054t
 for osteomyelitis, 840t, 841t
 for otitis externa, 229
 for *P. aeruginosa* infections, 808t, 1045t
 for perichondritis, 228
 for peritonitis prophylaxis, 847
 for plague prophylaxis, 1075t
 for plague treatment, 261e-5, 261e-5t, 1075
 for pouchitis in IBD, 1960
 for pyelonephritis, 867
 for Q fever, 1162
 resistance to
 in *Campylobacter* spp., 1061
 in *E. coli*, 862
 mechanisms of, 931t
 rates of, 941t
 in *S. pneumoniae*, 807
 for *Salmonella* infection prophylaxis, in HIV infection, 1252t
 for sepsis/septic shock, 1757t
 for *Shigella* infections, 1058, 1058t
 for tularemia, 261e-5t, 261e-7
- Circadian cycle, 400e-6
- Circadian pacemaker, 193
- Circadian rhythmicity, 186-187, 194, 2310, 2310f
- Circadian rhythm sleep disorders, 193-194
- CIRCI (critical illness-related corticosteroid deficiency), 1755, 1757
- Circinate balanitis, 2174
- Circle of Willis aneurysm, 1525
- Circulating endothelial precursors, 102e-14f
- Circulatory integrity, maintenance of, 296-297, 297f
- Circumcision, HIV infection risk and, 1221, 1285
- Cirrhosis
 alcoholic, 2058-2059, 2059f, 2075. *See also* Alcoholic liver disease
 in α_1 -AT deficiency, 2062
 autoimmune hepatitis and, 2060
 biliary. *See* Biliary cirrhosis
 cardiac, 2062
 clinical features of, 2058
 ascites, 286f, 287
 clubbing, 250
 cyanosis, 249
 diarrhea, 269
 edema, 252, 252t
 esophageal varices, 277
 gynecomastia, 2366
 hyponatremia, 299
 jaundice, 284
 pleural effusion, 1717
 splenomegaly, 411
 testicular atrophy, 2366
 coagulation disorders in, 739
 complications of, 2062, 2062t
 acute kidney injury, 1800, 1809-1810
 ascites. *See* Ascites
 bone disease, 2067
 coagulopathy, 2067
 encephalopathy. *See* Encephalopathy, hepatic
 hematologic abnormalities, 2067
 hepatorenal syndrome, 1800, 1809-1810, 2066
 hypersplenism, 2064
 malnutrition, 2066
 portal hypertension. *See* Portal hypertension
 splenomegaly, 2064
 spontaneous bacterial peritonitis, 2065-2066
 cryptogenic, vs. autoimmune hepatitis, 2051
 in cystic fibrosis, 2062
 definition of, 2031, 2058
 etiology of, 2058, 2059t
 global considerations in, 2059-2060
 HBV infection and, 2031, 2060
 HCV infection and, 2041, 2059-2060
 in hematocromatosis, 2062
 hepatocellular carcinoma and, 545, 545t
 Laennec's, 282
 liver biopsy in, 366e-3f, 366e-4f
 liver transplantation for, 2068, 2068t
 in NAFLD/NASH, 2054-2055, 2060
 pathogenesis of, 286
 pathology of, 2058
 physical examination in, 282-283
 postnecrosis, vs. autoimmune hepatitis, 2051
 recurrent, after liver transplantation, 2073-2074
 staging of, 1994-1995, 1995t
 treatment of, 1995, 2060
 tumor markers in, 473t
 in Wilson's disease, 2062
- Cisapride, 42t
- Cisplatin
 action of, 103e-12
 adverse effects of, 103e-9t, 103e-12, 590
 cardiotoxicity, 1563
 electrolyte disturbances, 64e-8, 103e-12, 306
 gonadal dysfunction, 103e-25
 hearing loss, 219, 622
 hemolytic-uremic syndrome, 1796
 nausea and vomiting, 103e-12, 103e-25, 474
- nephrotoxicity, 1804
 neurologic, 607, 607t, 622, 1793, 2686t
 neutropenic enterocolitis, 1798
 Raynaud's phenomenon, 103e-12, 1649
 for bladder cancer, 577
 for carcinoma of unknown primary, 120e-4
 for cervical cancer, 596
 for cholangiocarcinoma, 553
 for gastric cancer, 535
 for gestational trophoblastic disease, 597
 for head and neck cancer, 505
 for hepatocellular carcinoma, 550
 for lung cancer, 517-518, 518t, 520t, 521t, 522
 for melanoma, 499
 for osteosarcoma, 119e-3
 for ovarian germ cell tumors, 594
 for salivary gland tumor, 506
 for squamous cell carcinoma, 502
 for testicular cancer, 590, 591
 for thymoma, 123e-2
- Cisternography, CT, 440e-2
- Citalopram
 adverse effects of, 2640t, 2710t, 2716
 for depression, 64, 2710t, 2716
 for irritable bowel syndrome, 1969
- Citrate
 in transfusions, 138e-5
 urinary, 1867, 1870
- Citrobacter* spp. infections, 486t, 862, 1034-1035
- Citrulline, 435e-2
- Citrullinemia, 545, 545t
- Citrullinemia type 2 (citrin deficiency), 434e-3t, 435e-1t, 435e-2
- CJD. *See* Creutzfeldt-Jakob disease (CJD)
- CK. *See* Creatine kinase (CK)
- CKD. *See* Chronic kidney disease (CKD)
- c-kit*, 2114, 2115-2116
- c-kit* mutations
 in gastrointestinal stromal tumor, 119e-1
 imatinib response and, 39t, 536
 in melanoma, 499
 in ovarian germ cell tumors, 594
 in thymoma, 123e-2
- Cladophialophora*, 1355
- Cladribine, 135e-2, 682, 706, 718, 2121
- CLAH (congenital lipoid adrenal hyperplasia), 2324t
- Clarithromycin
 action of, 205e-8, 931, 931t, 943
 adverse effects of, 205e-8, 943
 for *Bartonella* infection prophylaxis in HIV infection, 1252t
 for community-acquired pneumonia, 808t
 drug interactions of, 42t, 205e-8, 246e-3t, 943, 2235
 for endocarditis prophylaxis, 826t
 in *H. pylori* eradication, 1042t, 1922t, 1923
 indications for, 940t, 943
 for *Legionella* infections, 1020t
 for MAC infection prophylaxis in HIV infection, 1251t
 for nontuberculous mycobacterial infections, 205e-8
 for pertussis, 1024t
 for pneumonia, 953
 in pregnancy and lactation, 937t
 resistance to, 931t, 940t, 1042
- Clasp-knife phenomenon, 154
- Classism, 16e-4
- Class switch, 710
- Claude's syndrome, 208, 2575, 2575f
- Claudication
 in aortic occlusion, 1642
 intermittent, 291e-4, 1616, 1643. *See also* Peripheral artery disease
 neurogenic, 115
 physical examination in, 1446, 1446f
 in thromboangiitis obliterans, 1645
- Claustrophobia, 2712
- Clavulanate, 933
- Clavulanic acid, 284
- CLCN5* gene mutations, 332e-8, 2459
- CLDN16* gene mutations, 332e-8
- Clearance, of drugs, 35